KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Payables (2018 - 2026)

Twist Bioscience has reported Payables over the past 9 years, most recently at $14.7 million for Q1 2026.

  • Quarterly Payables rose 82.09% to $14.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.7 million through Mar 2026, up 82.09% year-over-year, with the annual reading at $11.1 million for FY2025, 580.61% up from the prior year.
  • Payables was $14.7 million for Q1 2026 at Twist Bioscience, up from $12.5 million in the prior quarter.
  • Over five years, Payables peaked at $21.0 million in Q2 2022 and troughed at $1.6 million in Q3 2024.
  • The 5-year median for Payables is $12.1 million (2023), against an average of $12.2 million.
  • Year-over-year, Payables crashed 53.98% in 2023 and then surged 580.61% in 2025.
  • A 5-year view of Payables shows it stood at $20.1 million in 2022, then crashed by 53.98% to $9.3 million in 2023, then fell by 18.94% to $7.5 million in 2024, then skyrocketed by 66.51% to $12.5 million in 2025, then grew by 17.52% to $14.7 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Payables are $14.7 million (Q1 2026), $12.5 million (Q4 2025), and $11.1 million (Q3 2025).